GHK-Cu

Skin & hair Research compound (not approved for human use)

Copper-binding tripeptide · also known as Copper peptide, GHK-Copper

For reference only — not medical advice. Figures are commonly reported values compiled from published sources and may be wrong or out of date. Many compounds listed are not approved for human use. Talk to a licensed clinician before using any compound.

GHK-Cu is a naturally occurring copper-binding tripeptide studied for skin, hair, and tissue-remodeling applications. It is used both in injectable research protocols and in topical formulations.

Commonly reported dosing (50 mg vial)

Reconstituted with 3 mL → 16.667 mg/mL.

Also sold in 100 mg vials.

Phase	Dose	Volume	U-100 units
Starting Weeks 1-4	1 mg	0.06 mL	6
Step Weeks 5-8	1.5 mg	0.09 mL	9
Standard Weeks 9-12 and beyond	2 mg	0.12 mL	12

Frequency: Once daily, 5 days per week, subcutaneous (topical formulations are also used) · Half-life: Short

Open in calculator

Commonly reported reconstitution steps

Vials are usually brought to room temperature (about 15-20 minutes) first.
3 mL of bacteriostatic water is added slowly down the inside wall of the 50 mg vial.
The vial is swirled gently until clear, not shaken.
This gives 16.67 mg/mL. Mixed vials are typically labeled with the date and refrigerated.

Storage

Before mixing: Sealed vials are commonly stored refrigerated (2-8 °C) and protected from light, or frozen for long-term storage.

After mixing: Reconstituted solution is commonly kept refrigerated (2-8 °C), protected from light, and not frozen.

Commonly used within 28 days of mixing.

How it works

GHK-Cu delivers copper to cells and is associated in research with modulation of genes involved in tissue remodeling, collagen synthesis, and antioxidant activity.

Researched for

Studied for skin quality, wound support, and collagen synthesis.
Investigated for hair-follicle effects in topical use.
Antioxidant-associated activity in research.

Notes

Calculations here use 3 mL for both 50 mg and 100 mg vials; a 5 mL volume is also reported for 50 mg vials.
Another commonly reported pattern is 2 mg three times per week (about 6 mg weekly).
Human studies tend to examine topical, wound-related or cosmetic formulations rather than injections.